<DOC>
	<DOCNO>NCT00402584</DOCNO>
	<brief_summary>The purpose study examine safety efficacy sibutramine prevent binge eat episode . Additionally study aim evaluate safety efficacy sibutramine reduce body weight subject binge-eating disorder .</brief_summary>
	<brief_title>A Study Examine Efficacy Safety MeridiaÂ® ( Sibutramine Hydrochloride ) Binge-Eating Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Feeding Eating Disorders</mesh_term>
	<mesh_term>Binge-Eating Disorder</mesh_term>
	<mesh_term>Bulimia</mesh_term>
	<mesh_term>Sibutramine</mesh_term>
	<criteria>Participants men woman age 18 65 Body Mass Index ( BMI ) &lt; 45 kg/m2 meet DSMIV criterion BED Participants exclude blood pressure &gt; 140/90 mm Hg pulse &gt; 95 beats/min history stroke , narrow angle glaucoma , cardiac disease , seizures , renal hepatic dysfunction use insulin , medication know affect body weight , certain psychoactive medication ( monoamine oxidase inhibitor , lithium , SSRIs , opioids ) current participation weight loss program surgical treatment obesity bulimia nervosa purge past 6 month alcohol drug abuse past 12 month current psychiatric condition treat psychoactive agent current major depressive disorder history anorexia nervosa , psychosis , bipolar disorder , suicide attempt psychotherapy within previous 2 month Women exclude pregnant , lactating , fertile , practice adequate contraceptive precaution</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>